Iovance Biotherapeutics Financial Statements (IOVA)
|
|
|
|
Report date
|
|
|
24.02.2022 |
28.02.2023 |
28.02.2024 |
27.02.2025 |
24.02.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
1.19 |
164.1 |
263.5 |
|
285.6 |
|
Operating Income, bln rub |
|
|
-342.7 |
-398.9 |
-460.6 |
-395.3 |
-403.4 |
|
-363.2 |
|
EBITDA, bln rub |
? |
|
-328.7 |
-377.7 |
-427.4 |
-351.7 |
-357.1 |
|
-326.8 |
|
Net profit, bln rub |
? |
|
-342.3 |
-395.9 |
-444.0 |
-372.2 |
-391.0 |
|
-353.9 |
|
|
OCF, bln rub |
? |
|
-227.9 |
-292.8 |
-361.8 |
-353.0 |
-302.4 |
|
-270.8 |
|
CAPEX, bln rub |
? |
|
37.6 |
20.4 |
22.3 |
11.1 |
33.8 |
|
34.2 |
|
FCF, bln rub |
? |
|
-265.5 |
-313.2 |
-384.1 |
-364.0 |
-336.2 |
|
-305.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
342.7 |
398.9 |
451.0 |
435.4 |
659.6 |
|
690.2 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
10.8 |
124.0 |
7.29 |
|
159.6 |
|
R&D, bln rub |
|
|
259.0 |
294.8 |
344.1 |
282.3 |
300.3 |
|
285.9 |
|
Interest expenses, bln rub |
|
|
0.000 |
2.99 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
777.3 |
664.0 |
780.4 |
910.4 |
913.2 |
|
925.7 |
|
Net Assets, bln rub |
? |
|
621.7 |
499.6 |
584.6 |
710.4 |
698.6 |
|
721.8 |
|
Debt, bln rub |
|
|
71.5 |
85.4 |
75.9 |
58.3 |
48.4 |
|
46.8 |
|
Cash, bln rub |
|
|
504.4 |
471.8 |
279.9 |
323.8 |
297.0 |
|
313.4 |
|
Net debt, bln rub |
|
|
-432.9 |
-386.4 |
-204.0 |
-265.5 |
-248.5 |
|
-266.7 |
|
|
Ordinary share price, rub |
|
|
19.1 |
6.39 |
8.13 |
7.40 |
2.73 |
|
3.70 |
|
Number of ordinary shares, mln |
|
|
153.4 |
159.3 |
235.1 |
289.9 |
357.3 |
|
418.5 |
|
|
Market cap, bln rub |
|
|
2 929 |
1 018 |
1 912 |
2 145 |
976 |
|
1 548 |
|
EV, bln rub |
? |
|
2 496 |
631 |
1 708 |
1 880 |
727 |
|
1 282 |
|
Book value, bln rub |
|
|
622 |
500 |
355 |
428 |
419 |
|
453 |
|
|
EPS, rub |
? |
|
-2.23 |
-2.49 |
-1.89 |
-1.28 |
-1.09 |
|
-0.85 |
|
FCF/share, rub |
|
|
-1.73 |
-1.97 |
-1.63 |
-1.26 |
-0.94 |
|
-0.73 |
|
BV/share, rub |
|
|
4.05 |
3.14 |
1.51 |
1.48 |
1.17 |
|
1.08 |
|
|
EBITDA margin, % |
? |
|
|
|
-35 949% |
-214.3% |
-135.5% |
|
-114.4% |
|
Net margin, % |
? |
|
|
|
-37 345% |
-226.8% |
-148.4% |
|
-123.9% |
|
FCF yield, % |
? |
|
-9.07% |
-30.8% |
-20.1% |
-17.0% |
-34.5% |
|
-19.7% |
|
ROE, % |
? |
|
-55.1% |
-79.2% |
-76.0% |
-52.4% |
-56.0% |
|
-49.0% |
|
ROA, % |
? |
|
-44.0% |
-59.6% |
-56.9% |
-40.9% |
-42.8% |
|
-38.2% |
|
|
P/E |
? |
|
-8.56 |
-2.57 |
-4.31 |
-5.76 |
-2.50 |
|
-4.38 |
|
P/FCF |
|
|
-11.0 |
-3.25 |
-4.98 |
-5.89 |
-2.90 |
|
-5.08 |
|
P/S |
? |
|
|
|
1 608 |
13.1 |
3.70 |
|
5.42 |
|
P/BV |
? |
|
4.71 |
2.04 |
5.38 |
5.01 |
2.33 |
|
3.42 |
|
EV/EBITDA |
? |
|
-7.59 |
-1.67 |
-4.00 |
-5.34 |
-2.04 |
|
-3.92 |
|
Debt/EBITDA |
|
|
1.32 |
1.02 |
0.48 |
0.76 |
0.70 |
|
0.82 |
|
|
R&D/CAPEX, % |
|
|
689.4% |
1 443% |
1 544% |
2 551% |
887.4% |
|
835.1% |
|
|
CAPEX/Revenue, % |
|
|
|
|
1 875% |
6.75% |
12.8% |
|
12.0% |
|
| Iovance Biotherapeutics shareholders |
